5 Things Amgen, Inc.'s Management Wants You to Know

Amgen recently delivered 11% sales growth in the second-quarter, but is this sustainable? Find out what Amgen has up its sleeve in the coming years directly from its management team and how its strategies could affect your investment.

Aug 11, 2014 at 4:25PM

Amgen (NASDAQ:AMGN) reported its second-quarter earnings results two weeks ago, delivering yet another quarter of impressive growth and boosting full-year guidance.

During the quarter, Amgen announced that total revenue had increased 11% to $5.18 billion from the year-ago period as adjusted earnings per share vaulted higher by 25% to $2.37.

But earnings reports generally only let you scratch the surface of a company's performance. That's why it's always important to dig deeper and hear what management has to say about the current and future state of a company.

Today, let's examine five important quotes from management during Amgen's conference call, courtesy of S&P Capital IQ, and size up what this means for Amgen presently and down the road.  

Make or break time has arrived

"We've talked about our substantial portfolio of 10 late-stage molecules delivering pivotal data by 2016. So far in 2014, we've reported positive pivotal data for five of these molecules and we have submitted two of them already in the U.S." – Bob Bradway, Chairman, President, and CEO

Bradway is prepping investors for what should be 10 key late-stage and Food and Drug Administration decisions before the end of 2016.

Amgen Q2 slide presentation. Source: Amgen.

For investors it means we can expect plenty of catalysts and potentially more volatility than we've been accustomed to with Amgen. It's also the perfect opportunity for Amgen to reignite organic growth exclusive of acquisitions, share buybacks, and price hikes.

Late-stage trials and drug launches are expensive

"We'll reduce our workforce by between 2,400 and 2,900 positions, beginning in the fourth quarter of 2014 and continuing through 2015, predominantly in the United States. This represents approximately 12% to 15% of Amgen's global workforce of some 20,000 staff members." – Bob Bradway

And why is Amgen reducing its workforce? Because running large-scale stage 3 trials, manufacturing and stockpiling drugs for launch, and boosting a marketing staff and ad campaign surrounding new therapies is expensive.

Source: StockMonkeys.com, Flickr. 

Amgen's announced sweeping reforms that'll see 12% to 15% of its workforce laid off and cuts coming from every department, including research and development. These cuts accounted for $700 million in expenses in 2013, implying that not only will Amgen's expenses be lowered, resulting in EPS-boosting benefits, but that it'll be able to reallocate some of these savings toward the higher expenses associated with its drug launches.

There's a reason Amgen bought this company

"Kyprolis continues to maintain a dominant share in the third-line multiple myeloma setting. We expect the next major inflection point for Kyprolis will be upon the inclusion of second-line data in the label and look forward to reviewing the Aspire data in the near future." – Tony Hooper, Executive Vice President, Global Commercial Operations

Though Amgen hasn't expressed any interest in additional acquisitions, its management team is quick to remind investors that there's a good reason Amgen ponied up $10.4 billion for Onyx Pharmaceuticals – and a big part of that is multiple myeloma drug Kyprolis.

As a third-line treatment for multiple myeloma Kyprolis delivered $78 million in revenue in the latest quarter, up 15% globally and 23% in the U.S. sequentially. But, the real allure of Kyprolis is in potentially expanding its indication to second-line.

Last week, Amgen announced in its planned interim analysis that patients treated with injectable Kyprolis in combination with Revlimid and low-dose dexamethasone lived a median of 26.3 months without their disease worsening as compared 17.6 months for the control arm treated with Revlimid and low-dose dexamethasone. This significant difference should form the basis of a regulatory filing in the first half of 2015. More importantly, it opens the door for Kyprolis to gallop toward its peak annual sales projections on Wall Street of between $2 billion and $3 billion. 

Playing it safe

"In order to maximize the probability of a first cycle approval for evolocumab delivered via our auto-injector, we've decided to not include our automated mini doser device in the initial submission." – Sean Harper, Executive Vice President of Research and Development


Source: Dr. Farouk, Flickr.

Even though shareholders would prefer to see Amgen littering pharmacy shelves with newly approved compounds, Amgen is taking the cautious approach to drug approvals when necessary. Evolocumab, an investigational therapy to treat dyslipidemia, has reported solid LDL-C-reducing results that make it a strong potential candidate. 

However, Amgen noted its intent to hold back on seeking approval for its mini-doser. Instead, Amgen will seek approval for the device-drug combos which it feels most comfortable with and seek to add approval in conjunction with its once-monthly mini-doser shortly after initial approval. This is a smart move as it likely gives the injectable drug a better chance at approval, and also gives insurers more time to acquaint themselves with the product and presumably offer coverage.

This industry trend appears here to stay

"My take on the inversion activity is that unfortunately our country doesn't yet have a globally competitive corporate tax system or structure. And until that changes, I think there will be tax financial engineering-related transactions." – Bob Bradway

Finally, when asked about his take on tax inversions in general and whether or not Amgen would be interested in such a move by ISI Group analyst Mark Schoenebaum, Bradway made it abundantly clear that he anticipates sectorwide consolidation to continue under this premise.

Corporate tax inversion is the process by which as U.S.-based business buys a company on foreign soil and relocates its headquarters to the overseas address. Bradway conveyed his displeasure with the corporate tax structure as it is now and suggested that Congress reform existing laws.

Amgen receives a lot of its cash from ex-U.S. countries and a one-time repatriation of its cash could be a very positive move for the company. At the moment Amgen's effective tax rates are already among the lowest in the industry, but I wouldn't rule out the possibility in the intermediate to long-term if nothing is done about corporate tax inversion laws that Amgen could seek to change its address through a merger.

Amgen's new drugs may offer plenty of potential, but this revolutionary technology could wind up leaving Amgen in its dust!
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers